Virax Biolabs Group Limited
VRAX | NASDAQ
$2.50
+$0.19 (+8.23%)
At close: Sep 22, 2026, 4:00 PM ET
$2.50
$0 (0.00%)
After-hours:
Sep 22, 2026, 7:30 PM ET
Company Profile
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Key Executives
| Name | Position |
|---|---|
| James Foster | Chairman, Chief Executive Officer & Principal Accounting Officer |
| Nigel McCracken | Chief Operating Officer & Director |
| Clement Monteil | Head of Scientific Research & Development |
| Lily Fu | Head of Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 6-K | Filing |
| Sep 04, 2026 | 424B5 | Filing |
| Sep 03, 2026 | EFFECT | Filing |
| Sep 02, 2026 | F-3/A | [Amend] Filing |
| Aug 26, 2026 | 6-K | Filing |
| Aug 18, 2026 | 6-K | Filing |
| Jul 31, 2026 | 6-K | Filing |
| Jul 24, 2026 | F-3 | Filing |
| Jul 16, 2026 | 6-K | Filing |
| Jul 10, 2026 | 6-K | Filing |
Virax Biolabs Group Limited
| Country | United Kingdom |
| IPO Date | Jul 20, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | James Foster |
Contact Details
BioCity Glasgow Lanarkshire,
South Carolina ML1 5UH United Kingdom
Stock Details
| Ticker Symbol | VRAX |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001885827 |
| CUSIP Number | G9495L133 |
| ISIN Number | KYG9495L1335 |
| SIC Code | 2835 |
Add to Watchlist
Select watchlists to add or remove VRAX